Research

Clinical Trials

About this page

This section of the website is used to post information about relevant clinical trials in Canada as we are made aware of them. At the Foundation, we recommend you ask your doctor whether there are any clinical trials going on that you may be able to join. This has two benefits: firstly, you will have the opportunity to try new drugs that, hopefully, will come on the market and which may help you; and secondly, you are contributing to important research and that will make you feel good.

Clinical Trials and Drug Safety in Canada

Why Participate in a Clinical Trial

Dr. Gerard (Gerry) Cox talks briefly about what a clinical trial is, how a clinical trial is run, generally what drugs are being tested for IPF, and why you should participate in a clinical trial. The video is a recording of an interview with Dr. Cox shown to high school students from Hamilton, Ontario on December 2nd, 2013.

Clinical Trials in Canada

If you become aware of a relevant clinical trial for pulmonary fibrosis patients, please contact us at news.cpff@gmail.com and we will add it here.

Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis
Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov Identifier: NCT02632123

Study Locations as of March 6, 2018:  (Recruiting) London Health Science Centre, London, ON

Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea

Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea

ClinicalTrials.gov Identifier: NCT03018756

Study Locations as of January 12, 2018:  (Recruiting) Queen’s University, Kingston, ON

High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib (HOPE-IPF)

High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib (HOPE-IPF)

ClinicalTrials.gov Identifier: NCT02551068

Study Locations as of May 16, 2017:

(Recruiting) University of Alberta, Edmonton, AB; UBC Okanagan Kelowna, BC; St. Paul’s Hospital, Vancouver, BC; Queen’s University, Kingston, ON; McGill University, Montreal, QC; Laval University, Quebec City, QC

(Not yet recruiting) University of Calgary, Calgary, AB; McMaster University, Hamilton, ON

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

ClinicalTrials.gov Identifier: NCT03261037

Study Locations as of April 9, 2018:

(Recruiting) Hotel Dieu Hospital; Queen’s University; Department of Medicine, Kingston ON; Dr. Syed Anees Medicine Profession Corporation, Windsor, ON; Clinique de pneumologie et du sommeil de Lanaudiere, Saint-Charles-Borromee, QC

(Not yet recruiting) St. Clare’s Mercy Hospital, St. John’s, NL

Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension

Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension

ClinicalTrials.gov Identifier: NCT02951429

Study Locations as of April 9, 2018: (Recruiting) CHUM Hôpital Notre-Dame, Montreal, QC; Hôpital Laval, Ste. Foy, QC

The following studies are ongoing, but not recruiting participants.

Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment

ClinicalTrials.gov Identifier: NCT02802345

Study Locations as of February 14, 2018:  This study is active, but not recruiting participants.

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov Identifier: NCT01619085

Study Locations as of March 5, 2018:  Study is active but not recruiting participants.

Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis

Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov Identifier: NCT01890265

Study Locations as of February 7, 2018:  This study is active but not recruiting participants.

Efficacy and Safety of Nintedanib

Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

ClinicalTrials.gov Identifier: NCT02999178

Study Locations as of April 4, 2018:  (Recruiting) Hamilton, ON;  Toronto, ON

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

ClinicalTrials.gov Identifier: NCT03099187

Study Locations as of April 9, 2018:  (Recruiting) St. Paul’s Hospital, Vancouver, BC; St. Joseph’s Healthcare, Hamilton, ON; Hôpital Laval, Ste. Foy, QC

No active Canadian study locations as of April 10, 2018